Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

social care

- PMLiVE

Sanofi/Regeneron’s Dupixent receives CHMP recommendation for prurigo nodularis

Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

- PMLiVE

Best practice in UK dermatology care celebrated at second national awards

NHS teams from the Isle of Wight, Northern Ireland and London were among those recognised at the second annual Quality in Care Dermatology Awards

- PMLiVE

Dermavant’s Vtama shows promise in paediatric atopic dermatitis trial

The trial included children aged between two to 17 years and the treatment was well tolerated

- PMLiVE

Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial

How Pharma, Payers, & Providers are Leveraging Patient Self-Management Platforms

Rick Anderson, President of DarioHealth, explores digital therapeutics, how DarioHealth is utilizing AI and behavioral science to personalize each user’s health journey, and how this approach can help improve diversity...

Impetus Digital

- PMLiVE

Almirall granted EMA approval for lebrikizumab in atopic dermatitis

The Marketing Authorization Application is based on three pivotal phase 3 studies

Expanding Opportunities for Healthcare with “Digital Twins”

Brad Womble, Senior Director of Strategy, Marketing and Mergers & Acquisitions, at Jabil Healthcare dives into several thought-provoking topics, including how insights from “digital twins” can be used to improve...

Impetus Digital

- PMLiVE

Innovative Trials on the latest ABPI report

Kate Shaw, Innovative Trials Founder & CEO, commented on the latest ABPI report

Innovative Trials

- PMLiVE

Janssen’s Tecvayli granted FDA approval for multiple myeloma

A phase 2 study demonstrated an overall response rate of 61.8% in Tecvayli-treated patients

- PMLiVE

Innovative Trials featuring in a Clinical Trials Arena article

Leanne Keem, Head of Operations and Client Relationship at Innovative Trials, featured in a recent article.

Innovative Trials

- PMLiVE

Bristol Myers Squibb’s Opdivo shows promise as adjuvant melanoma treatment

The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival

- PMLiVE

WHO partners with IANPHI to strengthen health emergency preparedness

The two organisations will work together to enhance national public health capacities

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links